Dietary supplement of omega-3 fatty acids has no effect on acute collagen-induced thrombus formation in flowing native blood.
We have studied the effect of a daily supplement of 2.4 omega-3 fatty acids (omega 3 FAs) to 16 healthy men on acute collagen-induced thrombus formation in flowing non-anticoagulated blood. The supplement was formulated as Triomar capsules, containing 60% omega-3 FAs with an eicosapentaenoic/docosahexaenoic acid ratio of 3/2. A parallel-plate perfusion chamber device was used to study thrombus formation prior to and after 3 months of omega-3 FAs supplement. The wall shear rates at the thrombogenic surface were 650, 2,600 and 10,500 s-1, which are typical for small arteries, slightly stenosed arteries and severely stenosed arteries, respectively. For the latter situation a parallel-plate perfusion chamber with an eccentric stenosis occluding 80% of the cross-sectional area of the blood flow channel was used. The dietary supplement of omega-3 FAs did not cause significant changes in platelet adhesion to collagen or in thrombus volume. However, fibrin deposition was reduced by 34% (P < 0.03) at the highest shear condition (stenosis). Plasma fibrinogen was reduced by 18% (P < 0.0006). Changes in serum concentration of triglycerides, total-cholesterol, LDL- and HDL-cholesterol were not significant. Our data suggest that a moderate intake of omega-3 FAs provides virtually no protection against acute platelet-dependent thrombus formation, irrespective of the shear conditions. However, the significant reduction in plasma levels of fibrinogen following dietary supplementation of omega-3 FAs may be important, since high levels of fibrinogen is associated with cardiovascular disease and thrombosis.
Barstad
R M
RM
Nycomed Pharma AS, Oslo, Norway.
Roald
H E
HE
Petersen
L B
LB
Stokke
K T
KT
Kierulf
P
P
Sakariassen
K S
KS
D000328:Adult; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003094:Collagen; D004042:Dietary Fats, Unsaturated / Q000494:pharmacology* / Q000627:therapeutic use; D005227:Fatty Acids / Q000097:blood; D015525:Fatty Acids, Omega-3 / Q000494:pharmacology* / Q000627:therapeutic use; D005344:Fibrinopeptide A / Q000032:analysis; D006801:Humans; D008297:Male; D010743:Phospholipids / Q000097:blood; D013927:Thrombosis / Q000139:chemically induced / Q000517:prevention & control*; D001620:beta-Thromboglobulin / Q000032:analysis
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004042:Dietary Fats, Unsaturated; D005227:Fatty Acids; D015525:Fatty Acids, Omega-3; D010743:Phospholipids; D001620:beta-Thromboglobulin; D005344:Fibrinopeptide A; D003094:Collagen; D002784:Cholesterol